GTM for regulated markets (MedTech, FinTech, Food) requires additional considerations: (1) Regulatory timeline gates your launch date, (2) Clinical evidence is a sales prerequisite, (3) Reimbursement/payer landscape affects pricing, (4) Key Opinion Leaders (KOLs) drive adoption, (5) Compliance adds cost to every sales activity.
In MedTech, you can't sell without CE marking (EU) or FDA clearance (US). Build your GTM timeline around regulatory milestones, not product readiness.
Key Takeaways
- Regulatory approval gates everything — plan GTM around it.
- KOLs and clinical evidence drive adoption in healthcare.
- Reimbursement determines if customers CAN buy.
- Expect 6-18 month sales cycles in MedTech.
Frequently Asked Questions
What's the most important GTM milestone for a medical device startup?▼
Answer: Regulatory approval (CE/FDA)
You literally cannot sell without regulatory approval. Everything else is premature until this milestone is achieved.
Why are Key Opinion Leaders (KOLs) critical in MedTech GTM?▼
Answer: Physicians trust peer recommendations over sales pitches
In healthcare, physicians adopt new technology based on peer validation and published clinical evidence, not marketing campaigns.
What does reimbursement landscape mean for GTM?▼
Answer: Whether insurance/healthcare systems will pay for procedures using your device
If procedures performed with your device aren't reimbursed by insurance or national health systems, hospitals won't buy it regardless of how good it is.
The typical sales cycle for a medical device is:▼
Answer: 6-18 months
Medical device sales cycles are long due to: procurement committees, clinical evaluation, regulatory checks, budget cycles, and pilot requirements.